Q2 saw 11% adjusted EPS growth and 5% organic sales growth, with strong performance in Life Sciences, High-Tech, and Food & Beverage. Guidance for 2026 EPS was raised, and the 20% operating margin target for 2027 was reaffirmed, supported by robust pricing and volume momentum.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.